KAT2A and rheumatoid arthritis: To sum up, KAT2A drives the abnormal activation of NLRP3 inflammasome and excessive IL‐1β production in inflammatory macrophages by suppressing NRF2‐mediated metabolic reprogramming, resulting in the progressive articular damage in RA (Figure 8).